Genome Institute Plans Public Meeting on Future Funding
Published Date: 7/13/2026
Notice
Summary
The National Human Genome Research Institute is holding a public meeting on September 28-29, 2026, to share updates and review grant applications. Scientists, researchers, and anyone interested in human genetics can join in person or online. This meeting helps decide which projects get funding, so it impacts future research and innovation in genetics.
Analyzed Economic Effects
4 provisions identified: 4 benefits, 0 costs, 0 mixed.
Public may attend in person or online
You can attend the National Advisory Council for Human Genome Research meeting in person on September 28, 2026 (10:30 a.m. to 5:00 p.m.) at 6700 Rockledge Drive, Suite 3100, Rockledge, MD, or watch it live via the NIH Videocast at https://videocast.nih.gov/. The meeting includes an open session on September 28, 2026 and is limited to space available for in-person attendance.
Grant review session closed to public
The council will hold a closed session on September 29, 2026 from 10:30 a.m. to 5:00 p.m. to review and evaluate grant applications. The closure is under 5 U.S.C. 552b(c)(4) and (c)(6) to protect confidential trade secrets, commercial property, and personal information of applicants.
Anyone may file written comments
Any interested person may submit written comments to the committee by sending a statement to the Contact Person listed in the notice. The statement should include your name, address, telephone number, and, if applicable, your business or professional affiliation.
Reasonable accommodations available on request
If you plan to attend and need special assistance (for example, sign language interpretation or other reasonable accommodations), you should notify the Contact Person listed in the notice in advance of the meeting. This applies to the in-person meeting at 6700 Rockledge Drive and to arrangements for participation.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-17438, Center For Scientific Review; Notice of Closed Meetings
The NIH's Center for Scientific Review is holding several closed virtual meetings in late September 2026 to review and evaluate grant applications. These meetings protect private info and trade secrets, affecting researchers applying for funding. No direct money changes are announced, but these reviews decide who gets research grants.
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
Previous / Next Documents
Previous: 2026-14000, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in early August 2026 to review and evaluate important grant applications. These meetings protect private info and trade secrets while deciding which scientific projects get funding. Researchers applying for grants in areas like HIV, heart disease, and brain disorders should note these dates as they impact funding decisions.
Next: 2026-14002, Center For Scientific Review; Notice of Closed Meeting
The Center for Scientific Review is holding a closed virtual meeting on July 27, 2026, to review important grant applications about drug and biologic delivery. This meeting is private to protect secret ideas and personal info, affecting researchers waiting on funding decisions. No new money or timing changes are announced, but this review is a key step in moving science forward.